南宫NG·28(中国)相信品牌力量

Shanghai, China—Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd. (Endovastec™) was accredited as a “Shanghai Enterprise Technology Center” for its outstanding performance in developing technical talents and efforts in technological innovation, in the 2020 list of Municipal Enterprise Technology Centers in Shanghai (batch 26) recently released by Shanghai Municipal Economy and Information Technology Commission (SHEITC).

The accreditation of Shanghai Enterprise Technology Centers is an important initiative of the Shanghai Municipal Government, which aims to strengthen the development of a technological innovation system with enterprises as the backbone. The qualification is jointly accredited by the SHEITC together with the Shanghai Municipal Bureau of Finance, Shanghai Customs, and Shanghai Municipal Tax Service of the State Taxation Administration. Eligible enterprises are required to be an industry leader with strong innovation capabilities and high investment in research and development, in addition to ownership of core technologies, independent brand assets, and a stable mechanism for industry-academia-research cooperation. Looking at the comprehensive strength, R&D innovation capabilities, talent development and other aspects of candidate enterprises, the panel of expert reviewers shortlisted and approved 24 companies, including Endovastec™, in a review process comprising preliminary examination, expert evaluation and comprehensive assessment.

R&D innovation has always been a core driver of the rapid growth of Endovastec™, which established its own Technology Center in 2012, and developed full R&D capacity and a complete supply chain. As a result, it has been recognized as Pudong New Area Enterprise R&D Institution and MNC’s R&D Center. Endovastec™ holds a number of core technologies with independent intellectual property rights in the field of aortic and peripheral intervention. Its investment in R&D remains above industry average in recent years, and five products have entered the special approval procedure (“Green Path”) for innovative medical devices of the National Medical Products Administration (NMPA). Additionally, Endovastec™ has also established long-standing industry-academia-research innovation cooperation with a number of hospitals, universities and relevant institutions, which helps accelerate the commercialization of medical innovations.

“We will continue to rely on innovation as the engine that powers our development in field of aortic and peripheral interventional devices. We will build of our own brand and enhance our sustainable development capacity through scientific and technological innovation,” said Qing Zhu, Senior Vice President of Research and Development at Endovastec™. “In doing so, we aim to create more quality and affordable integrated medical solutions that save and reshape lives or improve quality of life, and thereby contributing to Shanghai’s efforts of pursuing innovation-driven transformation and development and becoming a global center of scientific and technological innovation,” he added.